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This is a mini dissertation comprising of 50% research project component. The University of 
KwaZulu-Natal CR13 (c) directs that a dissertation “may comprise one or more papers of which 
the student is the prime author, published or in press in peer-reviewed journals approved by 
the relevant college academic affairs board or in manuscripts written in a paper format, 
accompanied by introductory and concluding integrative material”. As such a standalone 
methodology is not required, as it forms part of the submitted paper/manuscript chapter. The 
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Background: The low availability of medicines in public health outlets coupled with 
unaffordable prices in the private sector can be a major barrier to medicines’ access. Patients in 
Eswatini may be forced to buy medicines from the private sector due to the chronic medicines 
shortages in Eswatini public health facilities. The extent to which they can afford to do so is 
unknown. 
Aim: To determine the availability,  prices paid by patients and affordability of medicines, in 
the retail pharmacies in Eswatini and to compare the results regionally. 
Setting: Retail pharmacy sector in the 4 administrative regions of Eswatini. 
Methods: Data on availability, prices and affordability to patients for two products namely the 
originator brand (OB) and the lowest-priced generic equivalent (LPG) for 50 medicines were 
collected using the standardised World Health Organization/ Health Action International 
methodology. The data collection was conducted in 32 retail pharmacies in the 4 regions of 
Eswatini. Prices for each medicine were compared with South Africa.   
Results: The overall mean availability of all medicines in selected retail pharmacy outlets was 
(38.5%; SD=20.4%) for OBs and (80.9%; SD=19.0%) for LPGs. The overall median price ratio 
(MPR) in the surveyed pharmacies was 18.61 for the OBs and 4.67 for LPGs. Most standard 
treatments with LPGs cost less than a day’s wage whilst  OB’s cost more than a day’s wages. 
The differences between Eswatini and South African prices were statistically significant. 
Conclusion: There is a need to develop medicines pricing policies and price monitoring tools 
in the whole pharmaceutical chain in Eswatini to measure and monitor availability, 





Chapter 1: Introduction 
 
1.1 Background 
The price of medicines is a major contributing factor to lack of access to medicines in different 
countries.¹ Unavailability and/or low availability of essential medicines in the public health 
outlets may become a major barrier to medicines’ access especially when coupled with high 
unaffordable prices in the private sector. ² There is significant under-use of costly medicines in 
populations that do not have any medical insurance, and thus even the smallest price changes 
in drugs will impact adherence significantly among the poor.³ It is thus imperative that prices 
in the private sector be affordable to ensure equity access. ³˒⁴   
Medicines expenditure constitutes between 20% and 60% of health expenditure in low and 
middle-income nations compared to just 18% in European nations. In developing countries, 
only a mere 10% has health insurance and the rest buy medication through out-of-pocket 
payments, thus making medication the largest family expenditure item after food. ⁵  
Nobrega et al.⁶  assert that the lack of medicines pricing legislation in the private sector and 
poor distribution of essential medicines in the public facilities negatively affect accessibility 
and burden consumers with out-of-pocket expenses. Patients in Eswatini may be forced to buy 
medicines from the private sector due to the chronic medicines shortages in Eswatini public 
health facilities.⁷  The extent to which they can afford to do so is unknown. 
The World Health Organisation/Health Action International (WHO/HAI) has set a benchmark 
of 80% medicine availability as high to ensure the supply of essential medicines. ⁸ Although 
generic medicines are way cheaper than the innovator brands, they are still relatively 
unaffordable in many parts of developing countries. ⁹ 
Cross national differences in pharmaceutical prices are of great importance as they help 
governments to come up with appropriate domestic pricing policies.¹⁰ However as Mhlanga et 
al ⁷ highlighted, there is a need to have reliable evidence on medicines’ prices in order to 
ascertain the type of challenges in a country before deciding on solutions that will ensure 
availability of essential medicines at the lowest price to the consumer. 
There is currently no price regulation of pharmaceuticals in Eswatini,⁷ although the Medicines 
and Related Substances Act of 2016, Section 54 makes provision for the Minister of Health, on 
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the recommendation of the Authority to prescribe a pricing system for all medicines and 
scheduled substances.¹¹ 
Availability, pricing and affordability surveys have been used to determine the extent of price 
differentiation and affordability in many countries.¹⁰˒¹²˒¹³˒¹⁴ Thus, for Eswatini, the WHO/HAI 
medicine price survey was used to identify medicine pricing and affordability in the Kingdom 
of Eswatini so as to provide policy makers and all stakeholders with evidence to draft policies 
that may improve availability, affordability and accessibility of medicines. 
The aim of this study was to investigate the availability, affordability and prices that people pay 
for medicines in different parts of Eswatini. In addition, this study sought to ascertain how the 
medicines’ prices in Eswatini compared to the prices of the same medicines in South Africa. 
Eswatini does not have any pharmaceutical manufacturing companies and depends on South 
Africa for most of their medications especially in the private market. The few medical aids 
operating in Eswatini are managed by South African administrators and their reimbursement 
schemes are extrapolated from the South African standards. It was thus important to compare 
Eswatini pricing to South Africa.  
1.2 Research problem 
There has been reported low availability of essential medicines in public health outlets ⁷ and 
patients may be forced to buy these medicines from the private pharmacy sector. The extent to 
which they can afford to do so is unknown. The research then sought to investigate the 
availability, affordability and prices that people pay for medicines in different parts of Eswatini. 
1.3 The objectives of the study 
The cross-sectional study investigated the availability, affordability and prices that people pay 
for medicines in different parts of the Kingdom of Eswatini for 50 medicines (14 from the 
global core list and 36 supplementary medicines). Data were collected from selected retail 
pharmacies in all the four administrative regions of the Kingdom of Eswatini. The study was 
designed: 
i. To determine the availability and prices that people pay for the key medicines in the 
retail pharmacies in the Kingdom of Eswatini. 
ii. To determine if the prices and availability of the key medicines varied in different parts 
of the country. 
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iii. To determine the affordability of medicines for the ordinary people, 
iv. To ascertain how the medicines’ prices in the Kingdom of Eswatini compared to the 
prices of the same medicines in South Africa. 
 
 
1.4 Research questions: 
 
i. What is the availability of key medicines and what prices do people pay for these 
medicines in the retail pharmacy sector in Eswatini? 
ii. Do prices and availability of the key medicines vary in different parts of the country? 
iii. How affordable are the key medicines for the ordinary people? 
iv. How do medicines’ prices in Eswatini compare to the prices of the same medicines 
in South Africa? 
1.5 Hypothesis 
There is anecdotal evidence that patient medicines prices and availability may vary with 
regional location. We hypothesized that medicines prices and availability would vary with 
location in Eswatini. Study area and general methodology 
Study design 
A quantitative cross-sectional descriptive study design was employed in this study. 
Setting 
The Kingdom of Eswatini is a small country, at just over 17000 km² and a population of just 
over a million people. The country is divided into 4 regions: Hhohho (North West), Manzini 
(central), Lubombo (East) and Shiselweni (South). An analysis of patient prices for 50 pre-
determined medicines (14 from global core list and 36 supplementary medicines) was 
conducted in 32 retail pharmacies in the 4 administrative regions of Eswatini using the 
WHO/HAI Standard Methodology.¹⁵  
Study Population and Sampling Strategy 
A list of pharmacies was obtained from the office of the Deputy Director of Pharmaceutical 
Services in the Ministry of Health of the 60 registered retail pharmacies in Eswatini at the time 
of the study; with 14 geographically situated in Hhohho, 30 in Manzini, 10 in Lubombo and 6 
4 
 
in the Shisweleni region. Stratified sampling was used to group the pharmacies. The primary 
criterion was the region of location for the pharmacy.  
A total number of 32 pharmacies were included in the study. Disproportionate stratified 
sampling was used to ensure that the sample was representative of the Eswatini retail pharmacy 
population. The sample comprised 12 pharmacies from Manzini, 8 from Hhohho, 6 from 
Lubombo and 6 from Shiselweni. Simple random sampling was used to select the pharmacies 
to use in each region. To analyze the effect of the size of the city/town on prescription prices; 
pharmacies were categorized as from either city or town/rural area.  
Data Collection 
Data collection took place between 15 June 2020 and 13 August 2020. The researcher collected 
the data.  Data on price, availability and affordability to patient were collected for two products, 
namely the originator brand (OB) and the lowest price generic (LPG) using the standardised 
WHO/HAI methodology,¹⁵ for 50 essential medicines (14 from the global core list and 36 
selected based on local relevance).¹⁶ The following specific data were collected using the 
WHO/HAI workbook, during visits to “retail pharmacy outlets”, 
1. the name of pharmacy, administrative region where located, and whether it was in a city 
or town/rural area. 
2. Brand/Product name and manufacturer of the lowest priced generic found at the site. 
3. Availability of the Originator brand and the lowest priced generic. 
4. Pack size and price of the pack found for the originator brand and the lowest priced 
generic. 
5. Any other comments regarding a given product. 
During the retail pharmacy visits, data was recorded on hard copy medicine prices data 
collection forms. The data collector made sure the data collection forms were complete and 
legible before leaving an outlet.  
Data collection forms were reviewed every day after completion of the field work to ensure 
data quality. The data was then entered from the hard copy forms into the electronic survey 
workbook, and the double entry program was run, and any mistakes corrected. Any 






Data were entered in the pre-programed WHO/HAI Microsoft Excel Workbook.¹⁷  The 
workbook automatically generated analysis of the data entered once complete giving summary 
tables of percentage availability and Median Price Ratios (MPR). Median local prices were 
expressed as ratios to international reference prices, using the formula. 
Medicine Price Ratio (MPR) = median local unit price 
                                              International reference unit price 
Management Sciences for Health (MSH)’s 2015 prices were used as the default source of  
international reference prices (IRP’s). The IRP’s used are prices offered to international not-for 
profit agencies for purchase of generics.¹⁸ 
The availability of medicines was determined as a percentage of outlets where medicine was 
found on the day of data collection. Mean availability of the 50 medicines was also reported. 
The differences in average percentage availability of OBs and LPGs determined if there was 
any variance in the availability of the two product types. To describe availability, the following 
ranges were used as reference, ⁸ 
1. < 30% extremely low 
2. 30% - 49% low 
3. 50% - 80% fairly high 
4. > 80% high. 
The MPR pharmacy prices for each drug was compared across region categories using analysis 
of variance (ANOVA). The MPR pharmacy prices for each drug were compared between the 
two categories of location size using t-test. The lowest and maximum prices in Eswatini were 
compared to the lowest and highest permissible retail prices in South Africa (based on current 
dispensing fee guide in South Africa at the time),¹⁹˒²⁰ and the differences were expressed as 
percentage price difference for similar products and were analysed using the t-test for statistical 
significance.  
Affordability was calculated as the number of wage days that the lowest paid government 
worker needed to spend to pay for treatment and was based on the median local price of a 
medicine prescribed at a standard dose. ¹⁵ All analysis were carried out using SPSS version 27. 
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1.6 Layout of thesis 
Chapter 1 
The introductory chapter elaborates on the significance of this study. The background and 
research problem are highlighted and the objectives, research questions and hypothesis for the 
study are discussed. The chapter concludes by describing the study area and the general 
methodology that was employed to meet the objectives. 
Chapter 2 
The literature review chapter explores and discusses the general principles, foundations and 
implications of medicines’ prices on availability and affordability of medicines to patients. 
Methods employed by policy makers to achieve price control and containment are also 
discussed. The chapter explains the current state of affairs with regards to medicines prices in 
Eswatini and South Africa. It concludes by discussing global studies that have employed the 
WHO/HAI methodology and their findings. 
Chapter 3 
This chapter presents the paper that was submitted to the African Journal of Primary Health 
Care and Family Medicine, as per the journal stipulated format and limitations in terms of 
graphs, tables and word count. 
Chapter 4 
The synthesis of the thesis is discussed in this chapter. Conclusions drawn from the primary 
research data are outlined in this chapter and the proposed recommendations are also discussed. 
Further research areas are highlighted and the chapter concludes by discussing the extent to 
which the study answered the research questions. 
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Chapter 2: Literature review 
2.1 Introduction 
Although medicines are crucial in the healthcare system, they are generally not affordable to 
people globally. It is well documented in literature that price is a major barrier to access.¹ 
Prohibitive pricing is one of the major barriers to essential medicines access.² There is 
significant under-use of costly medicines in populations that do not have any medical insurance, 
and thus even the smallest price changes in drugs will impact adherence significantly among 
the poor.³ 
More than 30% of world population does not have reliable access to essential medicines. In 
some of the poorest countries in Asia and Africa the proportion is as high as 50%.⁴ The price 
of drugs is a major contributing factor to lack of access in different countries.⁵ Unavailability 
and/or low availability of essential medicines in the public health outlets may become a major 
barrier to medicines’ access, especially when coupled with high unaffordable prices in the 
private sector.⁶ It is thus imperative that prices in the private sector be affordable to ensure 
equitable access. ⁷’⁸ 
Medicines’ expenditure constitutes between 20% and 60% of health expenditure in low and 
middle-income nations compared to just 18% in European nations. In developing countries, 
only a mere 10% has health insurance and the rest buy medication through out-of-pocket 
payments, thus making medication the largest family expenditure item after food. ⁹  
Different policy options are available to governments to regulate pharmaceutical pricing from 
free-pricing systems, price-regulated systems, price differentiation, price competition and 
discounts, to tendering procedures. ¹⁰ Different schemes are used globally to regulate drug 
prices; for example, France and Italy utilise drug price controls to directly manage the drug 
prices. In Germany and Japan prices are indirectly controlled via reimbursement under social 
insurance schemes. The National Pharmaceutical Price Authority in Britain monitors price by 
regulating the profits that companies make on branded prescription medicines’ sales. ¹¹ It is 
widely believed that the drug prices are generally higher in countries with less stringent price 
regulation (like the UK) or no regulation at all (the US) as compared to countries with strict 
price regulation.¹² 
The market share of innovator brands reduces significantly with the introduction of generics 
after the expiration of patent protection and the competition between the generic options lower 
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the prices of the branded products further.¹² Free-pricing systems may lower the medicines’ 
prices when optimum conditions are created; and as much as regulation in price-controlled 
systems may reduce the prices of both generics and brands, it may become a barrier to 
incentives to lowering prices below the listed ones.¹⁰  
Studies in the United States in price variability with other commodities besides 
pharmaceuticals, found that the poorer individuals usually find themselves paying more for 
similar goods and services as compared to their richer counterparts. ¹³ Grocery stores in poorer 
locations are usually smaller and more expensive than in the wealthier suburbs, mainly because 
of the existence of large chain stores in the more affluent areas and independents in the poorer 
areas. ¹³˒¹⁴ Not much is known about price regulation or affordability in low- and middle-income 
countries, especially across the African region. 
2.2 The Eswatini Experience 
The Kingdom of Eswatini has a Gross Domestic Product (GDP) per capita income of USD 3073 
and is classified as a lower middle-income country. More than 60% of the population are living 
below the upper poverty line of USD 8.21 per capita per month. ¹⁵ There is currently no price 
regulation of pharmaceuticals in Eswatini,¹⁶ although the Medicines and Related Substances 
Act of 2016, Section 54 makes provision for the Minister of Health, on the recommendation of 
the Authority to prescribe a pricing system for all medicines and scheduled substances.¹⁷ 
Mhlanga et al.¹⁶ highlighted the importance of reliable evidence on medicines’ prices in 
ascertaining the type of challenges in a system, before deciding on solutions to ensure 
availability of essential medicines at the lowest possible price to the consumer. 
Prices for prescription medicines are a significant obstacle to appropriate medicine use. ¹⁸ It is 
not easy to find reliable medicines prices’ information in developing countries, ¹⁹ including in 
Eswatini. The World Health Organisation/Health Action International (WHO/HAI) has set a 
benchmark of 80% medicine availability to ensure the supply of essential medicines. ²⁰ 
Although generic medicines are way cheaper than the innovator brands, they are still relatively 
unaffordable in many parts of developing countries. ²¹ 
The current Eswatini Medicines and Related Substances Act provides for the establishment of 
a medicines regulatory authority, whilst the Pharmacy bill provides for the establishment of 
pharmacy council, however both are not in existence.²² All prescription medicines (defined as 
any medicine on a valid doctor’s prescription), attract Value Added Tax (VAT) at zero percent 
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and where there is no prescription VAT at 15% is levied.¹⁷ Cross national differences in 
pharmaceutical prices are of great importance as they help governments to come up with 
appropriate domestic pricing policies.²³ 
2.3 Medicines’ Pricing in South Africa 
South Africa, as Eswatini’s neighbour, is considered as an upper middle-income country, and 
has introduced price controls for medicines. The Single Exit Price (SEP) mechanism lists the 
price that a medicine can be sold by a manufacturer to an end-dispenser. The South African 
Medicines and Related Substances Act (as amended) regulates the maximum additional 
dispensing fee that can be charged by people licenced to dispense as well as retail pharmacists,  
based on a tier-structure directly tied to the SEP. All retail medicines attract VAT at 15%. ²⁴ 
The Act has a provision that prohibits the use of bonuses, rebates or any incentives in the supply 
of medicines, to avoid undermining the SEP. ²⁵  
A study in South Africa investigated 50 medicines using the WHO/HAI methodology and the 
Interrupted Time-Series (ITS) model showed a significant decrease in medicines’ prices 
immediately after implementing the Single Exit Price (SEP) in 2004. ²⁶  
2.4 Pricing Surveys using the WHO/HAI methodology 
Pricing surveys have been used to determine the extent of price differentiation and affordability 
in countries. A survey conducted in Peru using the WHO/HAI Medicines Prices and 
Availability survey did not find any significant differences in overall availability or prices of 
the medicines under study by retail location. ¹⁵ 
Another study looked at the undiscounted prices for both innovator brand and the lowest priced 
generic for 25 essential medicines from 17 private pharmacies in Shaanxi province, Western 
China. It noted that generics were more available as compared to innovator brands and prices 
varied across different discount programs. The study concluded that price transparency of 
pharmaceuticals helps consumers in the identification of potential savings. ²⁷ 
An African study that used the standardized WHO/HAI methodology to measure medicines 
availability, prices and affordability in both public and private sectors was conducted from 
March 2012 to April 2013 in Sudan. The availability was generally low in both sectors with 
less than 10% for originator brands and less than 50% for the generics, and considerable price 
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differences noted between low priced generics (LPGs) and originator brands (OBs) of 
medicines. ²²  
A cross-sectional study on 50 essential medicines’ availability, prices and affordability was 
carried out in both private and public sectors in Malawi, using the standard WHO/HAI 
methodology. The availability of medicines was highest in the private retail pharmacy sector 
(71.1%), followed by 62.9% in Christian Health Association of Malawi facilities and private 
clinics had the least availability at 57.5%. It was noted that the cost of one course for more than 
half of the medicines under study exceeded the statutory minimum daily wage rendering them 
unaffordable to the biggest part of the population. ²⁸ 
Electronic questionnaires were used to carry out a study to assess the retail pricing, availability 
and affordability of medicines in private health facilities in low-income settlements within 
Nairobi County between September and December 2016. The availability of the indicator 
medicines varied amongst the different facilities ranging from 2% to 76%, whilst the retail 
prices were generally higher than IRPs. Although the different regions comprise people of 
similar social standing, price variations were noted amongst the different regions and this has a 
direct effect on accessibility of medicines. ²⁹ 
Guan et al.³⁰ findings highlighted the challenges associated with regional disparity and 
inequality between rural and urban areas in mainland China in the delivery of essential 
medicines. ³¹ 
Thus, for Eswatini, the WHO/HAI medicine price survey was used to identify medicine pricing 
and affordability in the Kingdom of Eswatini so as to provide policy makers and all stakeholders 
with evidence to draft policies that may improve availability, affordability and accessibility of 
medicines.  
The aim of this study was to investigate the availability, affordability and prices that people pay 
for medicines in different parts of Eswatini. In addition, this study sought to ascertain how the 
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Background: The low availability of medicines in public health outlets coupled with 
unaffordable prices in the private sector can be a major barrier to medicines’ access. Patients in 
Eswatini may be forced to buy medicines from the private sector due to the chronic medicines 
shortages in Eswatini public health facilities. The extent to which they can afford to do so is 
unknown. 
Aim: To determine the availability, prices paid by patients and affordability of medicines, in 
the retail pharmacies in Eswatini and to compare the results regionally. 
Setting: Retail pharmacy sector in the four  administrative regions of Eswatini. 
Methods: Data on availability, prices and affordability to patients for two products namely the 
originator brand (OB) and the lowest-priced generic equivalent (LPG) for 50 medicines were 
collected using the standardised World Health Organization/ Health Action International 
methodology. The data collection was conducted in 32 retail pharmacies in the 4 regions of 
Eswatini by the researcher. Prices for each medicine were compared with South Africa.   
Results: The overall mean availability of all medicines in selected retail pharmacy outlets was 
(38.5%; SD=20.4%) for OBs and (80.9%; SD=19.0%) for LPGs. The overall  MPR in the 
surveyed pharmacies was 18.61 for the OBs and 4.67 for LPGs. Most standard treatments with 
LPGs cost less than a day’s wage whilst  OB’s cost more than a day’s wages. Prices were higher 
in Eswatini and the differences between Eswatini and South African prices were statistically 
significant. 
Conclusion: There is a need to develop drug pricing policies and price monitoring tools in the 
whole pharmaceutical chain in Eswatini to measure and monitor availability, affordability, and 










Although medicines are crucial in the healthcare system, they are generally not affordable to 
people globally. It is well documented in literature that price is a major barrier to access.¹ 
Prohibitive pricing is one of the major barriers to essential medicines access.² There is 
significant under-use of costly medicines in populations that do not have any medical insurance, 
and thus even the smallest price changes in drugs will impact adherence significantly among 
the poor.³ 
More than 30% of world population does not have reliable access to essential medicines. In 
some of the poorest countries in Asia and Africa the proportion is as high as 50%.⁴ The price 
of drugs is a major contributing factor to lack of access in different countries.⁵ Unavailability 
and/or low availability of essential medicines in the public health outlets may become a major 
barrier to medicines’ access, especially when coupled with high unaffordable prices in the 
private sector.⁶ It is thus imperative that prices in the private sector be affordable to ensure 
equity access. ⁷˒⁸ 
Medicines expenditure constitutes between 20% and 60% of health expenditure in low and 
middle-income nations compared to just 18% in European nations. In developing countries, 
only a mere 10% has health insurance and the rest buy medication through out-of-pocket 
payments, thus making medication the largest family expenditure item after food. ⁹  
Different policy options are available to governments to regulate pharmaceutical pricing from 
free-pricing systems, price-regulated systems, price differentiation, price competition and 
discounts, to tendering procedures. ¹⁰ Different schemes are used globally to regulate drug 
prices; for example, France and Italy utilise drug price controls to directly manage the drug 
prices. In Germany and Japan prices are indirectly controlled via reimbursement under social 
Insurance schemes. The National Pharmaceutical Price Authority in Britain monitors price by 
regulating the profits that companies make on branded prescription medicines’ sales. ¹¹ It is 
widely believed that the drug prices are generally higher in countries with less stringent price 
regulation (like the UK) or no regulation at all (the US) as compared to countries with strict 
price regulation.¹² 
The market share of innovator brands reduces significantly after the introduction of generics 
after the expiration of patent protection and the competition between the generic options lower 
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the prices of the branded products further.¹² Free-pricing systems may lower the medicines’ 
prices when optimum conditions are created; and as much as regulation in price-controlled 
systems may reduce the prices of both generics and brands, it may become a barrier to 
incentives to lowering prices below the listed ones.¹⁰  
Studies in the United States in price variability with other commodities besides 
pharmaceuticals, found that the poorer individuals usually find themselves paying more for 
similar goods and services as compared to their richer counterparts. ¹³ The grocery stores in 
poorer locations are usually smaller and more expensive than in the wealthier suburbs, mainly 
because of the existence of large chain stores in the more affluent areas and  independents in 
the poorer areas. ¹³˒¹⁴ Not much is known about price regulation or affordability in low and 
middle income countries, especially across the African region. 
The Kingdom of Eswatini has a Gross Domestic Product (GDP) per capita income of USD 3073 
and is classified as a lower middle-income country. More than 60% of the population are living 
below the upper poverty line of USD 8.21 per capita per month. ¹⁵ There is currently no price 
regulation of pharmaceuticals in Eswatini,¹⁶ although the Medicines and Related Substances 
Act of 2016, Section 54 makes provision for the Minister of Health, on the recommendation of 
the Authority to prescribe a pricing system for all medicines and scheduled substances.¹⁷ 
Mhlanga et al.¹⁶ highlighted the importance of reliable evidence on medicines’ prices in 
ascertaining the type of challenges in a system, before deciding on solutions to ensure 
availability of essential medicines at the lowest possible price to the consumer. 
Prices for prescription medicines are a significant obstacle to appropriate medicine use. ¹⁸ It is 
not easy to find reliable medicines prices’ information in developing countries, ¹⁹ including in 
Eswatini. The World Health Organisation/Health Action International (WHO/HAI) has set a 
benchmark of 80% medicine availability  to ensure the supply of essential medicines. ²⁰ 
Although generic medicines are way cheaper than the innovator brands, they are still relatively 
unaffordable in many parts of developing countries. ²¹ 
The current Eswatini Medicines and Related Substances Act provides for the establishment of 
a medicines regulatory authority, whilst the Pharmacy bill provides for the establishment of 
pharmacy council, however both are not in existence.²² All prescription medicines (defined as 
any medicine on a valid doctor’s prescription), attract Value Added Tax (VAT) at zero percent 
and where there is no prescription VAT at 15% is levied.¹⁷ Cross national differences in 
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pharmaceutical prices are of great importance as they help governments to come up with 
appropriate domestic pricing policies.²³ 
South Africa, as Eswatini’s neighbour, is considered as an upper middle-income country, and 
has introduced price controls for medicines. The Single Exit Price (SEP) mechanism lists the 
price that a medicine can be sold by a manufacturer to an end-dispenser. The South African 
Medicines and Related Substances Act (as amended) regulates the maximum additional 
dispensing fee that can be charged by people licenced to dispense as well as retail pharmacists,  
based on a tier-structure directly tied to the SEP. All retail medicines attract VAT at 15%. ²⁴ 
The Act has a provision that prohibits the use of bonuses, rebates or any incentives in the supply 
of medicines, to avoid undermining the SEP. ²⁵  
Pricing surveys have been used to determine the extent of price differentiation and affordability 
in countries. A survey conducted in Peru using the WHO/HAI Medicines Prices and 
Availability survey did not find any significant differences in overall availability or prices of 
the medicines under study by retail location. ¹⁵ 
Another study looked at the undiscounted prices for both innovator brand and the lowest priced 
generic for 25 essential medicines from 17 private pharmacies in Shaanxi province, Western 
China. It noted that generics were more available as compared to innovator brands and prices 
varied across different discount programs. The study concluded that price transparency of 
pharmaceuticals helps consumers in the identification of potential savings. ²⁶ 
An African study that used the standardized WHO/HAI methodology to measure medicines 
availability, prices and affordability in both public and private sectors was conducted from 
March 2012 to April 2013 in Sudan. The availability was generally low in both sectors with 
less than 10% for originator brands and less than 50% for the generics, and considerable price 
differences noted between low priced generics (LPGs) and originator brands (OBs) of 
medicines. ²²  
A cross-sectional study on 50 essential medicines’ availability, prices and affordability was 
carried out in both private and public sectors in Malawi, using the standard WHO/HAI 
methodology. The availability of medicines was highest in the private retail pharmacy sector 
(71.1%), followed by 62.9% in Christian Health Association of Malawi facilities and private 
clinics had the least availability at 57.5%. It was noted that the cost of one course for more than 
22 
 
half of the medicines under study exceeded the statutory minimum daily wage rendering them 
unaffordable to the biggest part of the population. ²⁷ 
Electronic questionnaires were used to carry out a study to assess the retail pricing, availability 
and affordability of medicines in private health facilities in low-income settlements within 
Nairobi County between September and December 2016. The availability of the indicator 
medicines varied amongst the different facilities ranging from 2% to 76%, whilst the retail 
prices were generally higher than IRPs. Although the different regions comprise people of 
similar social standing, price variations were noted amongst the different regions and this has a 
direct effect on accessibility of medicines. ²⁸ 
Guan et al.³¹ findings highlighted the challenges associated with regional disparity and 
inequality between rural and urban areas in mainland China in the delivery of essential 
medicines. ²⁹ 
Thus, for Eswatini, the WHO/HAI medicine price survey was used to identify medicine pricing 
and affordability in the Kingdom of Eswatini so as to provide policy makers and all stakeholders 
with evidence to draft policies that may improve availability, affordability and accessibility of 
medicines.  
The aim of this study was to investigate the availability, affordability and prices that people pay 
for medicines from retail pharmacies in different parts of Eswatini. In addition, this study sought 
to ascertain how the medicines’ prices in Eswatini compared to the prices of the same medicines 
in South Africa. 
Research methods and design 
Study design 
A quantitative cross-sectional descriptive study design was employed in this study. 
Setting 
The Kingdom of Eswatini is a very small country, at just over 17000 km² and a population of 
just over a million people. The country is divided into 4 regions: Hhohho (North West), Manzini 
(central), Lubombo (East) and Shiselweni (South). An analysis of patient prices for 50 pre-
determined medicines (14 from global core list and 36 supplementary medicines) was 
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conducted in 32 retail pharmacies in the 4 administrative regions of Eswatini using the 
WHO/HAI Standard Methodology.  
Study Population and Sampling Strategy 
A list of pharmacies was obtained from the office of the Deputy Director of Pharmaceutical 
Services in the Ministry of Health of the 60 registered retail pharmacies in Eswatini at the time 
of the study; with 14 geographically situated in Hhohho, 30 in Manzini, 10 in Lubombo and 6 
in the Shisweleni region. Stratified sampling was used to group the pharmacies. The primary 
criterion was the region of location for the pharmacy.  
A total number of 32 pharmacies were included in the study. Disproportionate stratified 
sampling was used to ensure that the sample was representative of the Eswatini retail pharmacy 
population. The sample comprised 12 pharmacies from Manzini, 8 from Hhohho, 6 from 
Lubombo and 6 from Shiselweni. Simple random sampling was used to select the pharmacies 
to use in each region. To analyze the effect of the size of the city/town on prescription prices; 
pharmacies were categorized as from either city or town/rural area.  
Data Collection 
Data collection took place between 15 June 2020 and 13 August 2020. The researcher collected 
the data from the pharmacies. Data on price, availability and affordability to patient were 
collected for two products, namely the originator brand (OB) and the lowest price generic 
(LPG) using the standardised WHO/HAI methodology.³⁰ The following specific data was 
collected for 50 essential medicines as per the WHO listing ( 14 from the Global Core List and 
36 selected based on local relevance), ³¹using the WHO/HAI workbook,³² during visits to 
“retail pharmacy outlets”, 
1. the name of pharmacy, administrative region where located, and whether it was in a city 
or town/rural area. 
2. Brand/Product name and manufacturer of the lowest priced generic found at the site. 
3. Availability of the Originator brand and the lowest priced generic. 
4. Pack size and price of the pack found for the originator brand and the lowest priced 
generic. 
5. Any other comments regarding a given product. 
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During the retail pharmacy visits, data were recorded on hard copy medicine prices data 
collection forms. The data collector made sure the data collection forms were complete and 
legible before leaving an outlet.  
Data collection forms were reviewed every day after completion of the field work to ensure 
data quality. The data were then entered from the hard copy forms into the electronic survey 
workbook, and the double entry program was run, and any mistakes corrected. Any 
questionable data identified after running data checker, was investigated, and corrected. 
Data Analysis 
Data was entered in the pre-programed WHO/HAI Microsoft Excel Workbook.³²  The 
workbook automatically generated analysis of the data entered once complete giving summary 
tables of percentage availability and Median Price Ratios (MPR). Median local prices were 
expressed as ratios to international reference prices, using the formula.³⁰ 
Medicine Price Ratio (MPR) = median local unit price 
                                                International reference unit price 
Management Sciences for Health (MSH)’s 2015 prices were used as the default source of  
international reference prices (IRP’s). The IRP’s used are prices offered to international not-for 
profit agencies for purchase of generics.³³ 
The availability of medicines was determined as a percentage of outlets where medicine was 
found on the day of data collection. Mean availability of the 50 medicines was also reported. 
The differences in average percentage availability of OBs and LPGs determined if there was 
any variance in the availability of the two product types. To describe availability, the following 
ranges were used as reference, ¹⁹ 
5. < 30% extremely low 
6. 30% - 49% low 
7. 50% - 80% fairly high 
8. > 80% high. 
The MPR pharmacy prices for each drug was compared across region categories using analysis 
of variance (ANOVA). The MPR pharmacy prices for each drug were compared between the 
two categories of location size using t-test. The lowest and maximum prices in Eswatini were 
compared to the lowest and highest permissible retail prices in South Africa (based on current 
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dispensing fee guide in South Africa at the time),³⁴˒³⁵ and the differences were expressed as 
percentage price difference for similar products and were analysed using the t-test for statistical 
significance.  
Affordability was calculated as the number of wage days that the lowest paid government 
worker needed to spend to pay for treatment and was based on the median local price of a 
medicine prescribed at a standard dose.³⁰ All analysis was carried out using SPSS version 27. 
Results 
Medicines Availability on the day of data collection 
The overall mean availability of all medicines in the surveyed retail pharmacy outlets was 
(38.5%;SD=20.4%) for the Originator Brands (OBs) and (80.9%;SD=19.0%) for the Lowest 
Price Generics (LPGs). Table 1 highlights the mean availability of the different classes of 
medicines in the different regions.  
Although availability data only refers to the day of data collection, the availability of OBs was 
generally low in all the surveyed pharmacies with only Hhohho region recording more than 
50% availability (56.1%), whilst Manzini had 42.3% availability, 28.5% for Shiselweni and 
then Lubombo with 23.6% availability. ANOVA results showed there were significant 
differences between the regions in terms of OBs availability (F3,123 =15.236, p < 0.001). A 
post-hoc test (Bonferroni correction) showed that Hhohho had significantly higher OBs 
availability than Manzini, Shiselweni and Lubombo regions (p < 0.001). The difference 
between Manzini and Lubombo (p = 0.170), Manzini and Shiselweni (p = 1) and between 
Lubombo and Shiselweni (p = 1) were not statistically significant. 
The mean availability of LPGs was fairly high in Lubombo and Shiselweni and high in Manzini 
and Hhohho, with the highest availability of 83.3% recorded in Manzini, followed by 82.4% in 
the Hhohho region, then Shiselweni with 79.6% and lastly Lubombo region with an availability 
of 76.2%. The differences were not statistically different (p < 0.001).  
The overall mean availability of OBs in the surveyed outlets varied from 0% for medicines like 
simvastatin and glibenclamide to 88.5% for metformin. The higher mean availability of the 
LPGs was evident with 30 out of the 50 surveyed medicines recording more than 90% 
availability and 6 medicines with 100% availability. 
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Results showed that the pharmacies located within cities had a higher OBs mean availability (x 
= 54.3% , SD = 24.6%) as compared to the outlets situated in towns and rural areas (x = 28.6%, 
SD = 19.4%).The mean difference (25.7%) between the two locations was statistically 
significant (t = 10.26 (32); p = 0.001).  
The availability of LPGs was high in the city and fairly high in the town located pharmacies, 
with pharmacies in the cities registering 87.4% availability and the outlets in towns and rural 
areas recording 76.5% availability. Results showed that this difference was statistically 
significant: t = 4.658 (48), p = 0.001. 
























LPGS 83.3% 82.4% 79.6% 76.2% 80.9%  
OBs 42.3% 56.1% 28.5% 23.6% 38.6%  
Medicine Type       
Anti-infectives      8 
LPGs 85.7% 87.5% 88.9% 71.4% 86.7%  
OBs 37.5% 39.6% 23.3% 13.3% 30.7%  
NCD Medicines      42 
LPGs 82.9% 81.1% 83.3% 76.4% 82.3%  
OBs 41.9% 21.4% 29.2% 21.4% 38.5%  
Essential Medicines      38 
On EML       
LPGs 86.7% 88.9% 84.2% 80.2% 85.1%  
OBs 37.6% 57.2% 18.4% 25.6% 38.3%  
Not on EML      12 
LPGs 72.9% 69.8% 65.3% 62.5% 69.0%  
OBs 40.2% 49.0% 26.7% 19.4% 40.0%  
Sample List       
Global Core      14 
LPGs 89.3% 91.1% 88.1% 88.1% 89.2%  
OBs 41.7% 48.8% 35.0% 30.0% 40.0%  
Supplementary      36 
LPGs 81.0% 78.9% 76.2% 71.4% 77.7%  
OBs 42.6% 58.8% 26.2% 22.0% 38.0%  
OB, originator brand; LPG, lowest-priced generic equivalent; NCD, non-communicable diseases; EML, essential medicines list. 
The overall availability of all the different groups analysed was generally high for the LPGs 
and low for the OBs. The global core medicines had the highest LPGs mean availability 
(89.2%;SD=9.0%), followed by anti-infectives at 86.7%, then EML medicines with 85.1% 
mean availability, followed by 82.3% for the NCD medicines and then 77.7% overall mean 
availability for the supplementary medicines (Table 1). The differences between the different 
regions in terms of availability of LPGs of the different classes were not statistically significant. 
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A similar trend was observed with respect to availability of the different medicines’ groups in 
both cities and smaller towns and the rural areas.  
Consolidated Private Retail Sector Patient Price Ratios 
Of the 50 medicines surveyed in the 26 outlets, price ratios were calculated for 33 originator 
brands (OBs) and 48 lowest price generics (where medicines were found in 4 or more outlets). 
Overall, the Median Price Ratio (MPR) was 18.60 for the OBs whilst the MPR for the LPGs 
for Eswatini retail outlets was 4.51. The 25th and 75th percentile MPR for innovator brands were 
3.91 and 36.75 respectively, with an MPR range of 132.58 (0.70-133.28) and for the lowest 
price generics, they were 1.98 and 10.36 respectively, with 0.23 as the minimum MPR and 
60.72 as the maximum MPR. 
Regional Patient Prices Comparison 
Overall patient prices in Shiselweni were approximately 4% and 8% more than patient prices 
in Manzini region, whilst the Lubombo prices were approximately 42% and 9% more in 
comparison to Manzini for innovator brands and lowest price generics, respectively. The overall 
MPR patient prices in Shiselweni were approximately 7% cheaper than the prices in Hhohho 
for the LPGs.  ANOVA results showed there was no significant difference between the regions 
in terms of LPGs prices (F3,160 = .448, p< 0.719).  
Table 2. Eswatini MPRs comparison by location.  
 
Medicine Name (LPG) 










(n = 15) 
City  
(n = 11) 
Acyclovir 200mg cap/tab 5.79 5.66 5 33 5.02 5.53 5.6 
Amitriptyline 25mg cap/tab  9.98 11.07 9 27 12.47 10.00 10.79 
Amlodipine 5mg cap/tab 11.68 11.68 10.29 13.99 11.69 11.67 
Amoxicillin 500mg cap/tab 2.26 2.10 2.63 2 58 2.49 2.01 
Amoxicillin + clavulanic acid 125+31.25mg susp 0.23 0.21 0 20 0 30 0.26 0.22 
Anhydrous Theophylline 200mg cap/tab 3.85  - 3 19 3.73 3.63 3.85 
Atenolol 50mg cap/tab 8.00 6.71 12.08 4 20 7.88 8.11 
Atorvastatin 20mg cap/tab 0.97 0.92 0 99 1 37 1.09 0.87 
Azithromycin 500mg cap/tab 13.00 14.52 10.13 15.59 13.3 14.22 
Beclomethasone 100mcg/dose Inh 1.63 1.55 1 51 1 55 1.5 1.59 
Bisoprolol 5mg cap/tab 1.55 1.78 1 54 2.01 1.67 1.57 
Budesonide 0.5mg/ml Neb susp 59.44 62.40  -  - 61.27 60.72 
Captopril 25mg cap/tab 1.27 1.10 1.46 1 56 1.46 1.22 
Carbamazepine 200mg cap/tab 10.48 10.95 10.68 11.92 11.1 10.71 
Carvedilol 12.5mg cap/tab 1.31 1.31 1 31 1.43 1.32 1.31 
Ceftriaxone injection 1 g/vial  6.49 5.78 8 17 8 17 8.17 5.77 
Cetirizine 10mg cap/tab 14.77 16.97 14.98 17.75 16.62 15.06 
Ciprofloxacin 500mg cap/tab 6.51 6.89 7.47 7.85 7.46 6.7 
Co-trimoxazole suspension 8+40mg/5ml susp 2.12 1.90 2 36 2 39 2.3 1.87 
Diazepam 5mg cap/tab 2.22 1.00  -  - 6.58 1.12 
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Diclofenac 50mg cap/tab 6.51 7.09 9 57 9 57 9.57 6.64 
Enalapril 20mg cap/tab 12.30 14.55 9.45 16.96 12.33 12.54 
Fluoxetine 20mg cap/tab 2.12 3.63 3 33 3 58 3.41 3.27 
Fluticasone/Salmeterol 25/250mg Inh 10.16 11.01  - 10.80 10.8 11.01 
Furosemide 40mg cap/tab 2.12 9.38 6 59 7.69 6.59 4.33 
Glibenclamide 5mg cap/tab 4.69 4.60 4 14 6.05 4.47 4.47 
Gliclazide 80mg cap/tab 1.84 1.90 1.76 1.77 1.76 2.01 
Hydrochlorothiazide 25mg cap/tab 6.56 9.05 8.04 8.74 8.74 6.4 
Hydrochlorothiazide/Losartan 12.5/50mg cap/tab 1.78 1.79  -  - 1.6 1.79 
Irbesatan 150mg cap/tab 10.40 10.61 9 92 11.04 10.83 10.21 
Loratidine 10mg cap/tab 6.20 7.13 5 97 6 53 6.15 7.09 
Losartan 10mg cap/tab 1.93 2.13 1.72 2 22 1.92 2.07 
Metformin 500mg cap/tab 2.55 2.41 2 25 2 22 2.39 2.34 
Methyldopa 250mg cap/tab 2.57 2.65 2 39 2.66 2.66 2.47 
Montelukast 5mg cap/tab 6.61 7.07 7 14 7 25 7.14 7.03 
Nifedipine Retard 20mg cap/tab 4.80 4.64 4.41 5 19 4.55 4.57 
Omeprazole 20mg cap/tab 3.18 31.48 14.26 14.26 14.26 20.45 
Paracetamol suspension 24mg/ml susp 1.67 1.69 2.04 2 21 2.05 1.68 
Phenytoin 100mg cap/tab 4.94 4.99 5 20 5.84 5.52 4.98 
Propranolol 40mg cap/tab 3.57 3.02 3.45 4 16 3.83 3.42 
Risperidone 2mg cap/tab 57.91 62.09 50.40  - 54.41 60.59 
Salbutamol inhaler 100mcg/dose 1.57 1.58 1 35 1.65 1.46 1.55 
Salbutamol syrup 2mg/5ml 2.40 2.55 2.46 2.63 2.58 2.51 
Simvastatin 20mg cap/tab 1.79 1.86 1 58 1.70 1.68 1.86 
Sodium Valproate 200mg cap/tab 3.67 4.16 3.67 3 37 3.55 4.08 
Spironolactone 25mg cap/tab 3.06 3.22 2.84 2 98 2.98 3.11 
Tamsulosin 0.4mg cap/tab 10.60 11.13 10.72 10.81 10.76 10.72 
mg, milligrams per dosage form; cap/tab, capsules or tablets as a dosage form; mcg/dose, micrograms per dose of medicine. 
A few of the lowest price generics had large price differentials across the different regions. The 
LPG omeprazole 20mg cap/tab was sold to patients at 3.18MPR in Manzini, but was available 
at more than 4 times that price in Lubombo and Shiselweni regions, and in the Hhohho region 
the patients had to part with almost 10 times the Manzini price. The LPG furosemide was 
available at 2.12 MPR in Manzini, required more than 3 times this in Lubombo and Shiselweni 
and was available at 9.38 MPR in the Hhohho region. Atenolol 50mg, diclofenac 50mg and 
fluoxetine 20mg also showed large price differentials across the regions.  
Overall patient prices in the cities were 3% more and 5% less than patient prices in the smaller 
towns for innovator brands and lowest generic equivalents, respectively. The LPG diazepam 
5mg was available to patients at 1.12 MPR to patients in the cities whilst it was sold at 6.58MPR 
in the smaller towns. 
OBs price ratios were only analysed for Hhohho and Manzini regions as the other two regions 
did not have significant OBs availability for any meaningful comparison. Overall patient prices 
in Manzini were approximately 3% and 1% more than patient prices in the Hhohho region for 
innovator brands and lowest generic equivalents, respectively. Results showed that the 
difference between Manzini and Hhohho OBs medicines prices was not statistically significant: 
t = 1.432 (22), p = 0.166.   
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Comparison of retail prescription drug prices in the Kingdom of Eswatini and South 
Africa 
Of the 32 OB’s that were found in more than four (4) outlets in Eswatini only 2 products, 
diclofenac 50mg cap/tab and amlodipine 5mg cap/tab had their highest prices equal to the 
maximum permissible South African patient price, whilst 8 products had their Eswatini highest 
prices lower than the maximum permissible South African patient prices and the rest had 
Eswatini highest prices that were more than the maximum permissible South African patient 
prices. The differences were statistically significant: t = 3.10 (31), p = 0.004. Only one product, 
carvedilol 12.5mg cap/tab, had its lowest Eswatini unit price lower than the cheapest South 
African patient price, whilst the lowest prices for all the other OB’s were higher than the lowest 
prices in South Africa of the same products. The differences were statistically significant: t = 



























Salbutamol inhaler 100mcg/dose 1.91 0.72 +62% 0.51 0.41 +20% 
Sodium Valproate 200mg cap/tab 13.27 6.45 +51% 5.72 4.69 +18% 
Hydrochlorothiazide/Losartan 12.5/50mg cap/tab 14.68 7.80 +47% 6.09 4.85 +20% 
Human insulin 30/70 isophane 100iu/ml vial 77.14 49.25 +36% 41.11 33.88 +18% 
Risperidone 2mg cap/tab 55.40 35.44 +36% 35.94 27.52 +23% 
Carbamazepine 200mg cap/tab 9.67 6.98 +28% 6.66 4.58 +31% 
Bisoprolol 5mg cap/tab 9.29 7.18 +23% 5.12 4.40 +14% 
Fluticasone/Salmeterol 25/250mg Inh 17.51 15.27 +13% 14.55 11.67 +20% 
Montelukast 5mg cap/tab 25.99 23.06 +11% 19.86 16.78 +16% 
Omeprazole 20mg cap/tab 36.37 32.77 +10% 31.24 25.05 +20% 
Fluoxetine 20mg cap/tab 21.73 19.61 +10% 17.53 14.02 +20% 
Metformin 500mg cap/tab 1.49 1.36 +9% 0.86 0.70 +19% 
Phenytoin 100mg cap/tab 4.82 4.44 +8% 3.61 2.97 +18% 
Spironolactone 25mg cap/tab 2.84 2.63 +7% 1.84 1.52 +17% 
Tamsulosin 0.4mg cap/tab 18.78 17.38 +7% 14.01 12.12 +13% 
Atorvastatin 20mg cap/tab 21.20 19.77 +7% 15.25 14.15 +7% 
Irbesatan 150mg cap/tab 18.47 17.51 +5% 12.55 11.92 +5% 
Ciprofloxacin 500mg cap/tab 33.00 32.41 +2% 24.73 21.07 +15% 
Losartan 10mg cap/tab 7.11 7.02 +1% 5.02 4.28 +15% 
Budesonide 0.5mg/ml Neb susp 28.77 28.48 +1% 24.63 20.23 +18% 
Enalapril 20mg cap/tab 6.78 6.72 +1% 4.87 3.97 +18% 
Diclofenac 50mg cap/tab 6.06 6.04 0% 4.08 3.35 +18% 
Amlodipine 5mg cap/tab 11.28 11.30 0% 9.25 7.38 +20% 
Furosemide 40mg cap/tab 9.03 9.16 -1% 6.65 4.87 +27% 
Azithromycin 500mg cap/tab 107.29 109.53 -2% 85.58 71.32 +17% 
Atenolol 50mg cap/tab 13.21 13.53 -2% 11.25 9.00 +20% 
Nifedipine Retard 20mg cap/tab 14.82 15.54 -5% 14.28 11.90 +17% 
Loratidine 10mg cap/tab 5.98 6.69 -12% 2.61 2.00 +23% 
Carvedilol 12.5mg cap/tab 9.15 10.50 -15% 6.66 6.80 -2% 
Amoxicillin + clavulanic acid 125+31.25mg susp 2.05 2.38 -16% 1.66 1.48 +11% 
Cetirizine 10mg cap/tab 9.19 10.80 -18% 8.59 7.02 +18% 
mg, milligrams per dosage form; cap/tab, capsules or tablets as a dosage form; mcg/dose, micrograms per dose of medicine. 
Of the 48 LPGs analysed one product, tamsulosin had its Eswatini lowest price equal to South 
Africa’s lowest generic patient price, 26 products’ Eswatini lowest prices were higher than 
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South Africa’s lowest prices and 18 products had their lowest prices lower than corresponding 
South African lowest generic prices for the same molecules. The lowest prices of Simvastatin 
20mg and Omeprazole 20mg were more than 300% lower than the lowest generic patient prices 
in South Africa. The lowest and highest LPGs prices for South Africa were calculated using the 
Medicines Reference Prices (MRPs) from the Mediscor platform.³⁴  
Of all the LPGs that were analysed, only 11 products had Eswatini highest prices lower than 
the South African maximum permissible patient prices in the retail pharmacies and the other 37 
products had highest prices higher than the highest generic patient prices for similar molecules 
in South Africa. The difference in the prices was statistically significant:  t = 2.549 (47), p = 
0.014.  
Treatment affordability 
The LPGs for the most common anti-infectives were generally affordable in all the regions, 
with an adult 7-days’ course of amoxycillin, a paediatric 7-days’ course of cotrimoxazole and 
a paediatric 7-days course of amoxycillin + clavulanic acid, all requiring less than a day’s wages 
of the lowest paid government unskilled worker to purchase them. The OB for amoxycillin & 
clavulanic acid, however required 2.28 days’ wages in Manzini and 2.13 days’ wages in the 
Hhohho region. A single dose of 1g azithromycin for the treatment of Chlamydial infections 
was unaffordable for both LPGs and OBs in all the regions, save for Shiselweni region where 
purchasing the LPG course required only 0.94 days’ wages of the lowest paid unskilled 
government worker. 
A standard one-month treatment course for benign prostate hypertrophy (BPH) with tamsulosin 
0.4mg once daily was unaffordable in all the four regions for both the LPGs and OBs. The 
lowest paid unskilled government worker needed to work for 3 days to afford the LPG and 5.98 
days to be able to buy the OB in Manzini region. 
Management of depression with fluoxetine 20mg once daily, was affordable for the LPGs in all 
the regions requiring 0.56 days’ worth of wages of the lowest paid government unskilled worker 
Manzini, 0.88 days’ wages in Shiselweni, 0.95 days in Lubombo and 0.96 days in the Hhohho 
region (table 2). The OB was only available in Hhohho and required the lowest paid unskilled 
government employee to work 7.16 days to afford to purchase a course for one (1) month. 
The first line LPGs anti-hypertensives (hydrochlorothiazide, captopril and atenolol) were 
affordable in all the four (4) regions of Eswatini requiring less than a day’s wage to purchase a 
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course, with hydrochlorothiazide being the most affordable, requiring only under 0.25 day’s 
wages of the lowest paid unskilled government employee to purchase it. The second line and 
third line anti-hypertensives were generally unaffordable, requiring more than a day’s wages 
for both the OBs and LPGs, apart from the LPGs for enalapril 20mg in Manzini (0.86 days) and 
Shiselweni (0.66 days). 
Table 4. Affordability of selected LPG medicines   
 
Medicine 
Number of days’ wages needed to purchase a course of treatment 
Manzini Hhohho Shiselweni Lubombo 
Amoxicillin 500mg cap/tab                    0.29                      0.27  0.34 0.33 
Azithromycin 500mg cap/tab                    1.20                      1.35  0.94 1.45 
Beclomethasone 100mcg/dose Inh                    0.84                      0.80  0.78 0.80 
Carbamazepine 200mg cap/tab                    2.38                      2.48  2.42 2.70 
Enalapril 20mg cap/tab                    0.86                      1.02  0.66 1.19 
Fluoxetine 20mg cap/tab                    0.56                      0.96  0.88 0.95 
Fluticasone/Salmeterol 25/250mg/dose Inh                    5.94                      6.44  - 6.32 
Glibenclamide 5mg cap/tab                    0.33                      0.32  0.29 0.42 
Gliclazide 80mg cap/tab                    1.10                      1.14  1.05 1.06 
Human Insulin 100iu/ml Inj                    5.20                      5.36  - 7.37 
Hydrochlorothiazide 25mg cap/tab                    0.17                      0.24  0.21 0.23 
Ibersatan 150mg cap/tab                    1.89                      1.93  1.80 2.00 
Losartan 50mg cap/tab                    1.36                      1.50  1.22 1.57 
Metformin 500mg cap/tab                    0.47                      0.44  0.41 0.41 
Methyldopa 500mg cap/tab                    1.53                      1.58  1.42 1.59 
Montelukast 5mg cap/tab                    3.40                      3.63  3.67 3.73 
Nifedipine SR 20mg cap/tab                    1.20                      1.16  1.10 1.29 
Omeprazole 20mg cap/tab                    0.74                      2.72  1.23 1.23 
Salbutamol 100mcg/dose Inh                    0.18                      0.18  0.16 0.19 
Sodium valproate 200mg cap/tab                    3.13                      3.55  3.13 2.87 
Tamsulosin 0.4mg cap/tab                     .93                      3.08  2.97 2.99 
 
The three anti-epileptic medicines surveyed required more than a day’s wages to buy a course 
for one month, save for the LPGs for phenytoin 100mg tablets which required 0.94 days’ wages 
in Manzini and 0.95 days’ wages in the Hhohho region. To afford a course of sodium valproate 
for a month, the lowest paid government worker had to work for 4.52 days for the OB and 3.55 
days for the LPG. A similar trend was observed with carbamazepine as well, with the most 
affordable OB requiring 4.19 days’ wages whilst the most affordable LPG required 2.38 days’ 
wages to purchase a course. 
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A course of salbutamol inhaler required less than 0.2 days’ wages for the LPGs and just under 
0.5 days’ wages for the OB in all the regions where stock was available. Less than a single 
day’s wages were adequate to purchase a month’s supply of the LPGs of beclomethasone 
100mg inhaler in all the regions surveyed. Management of asthma with montelukast 5mg once 
daily was unaffordable for both LPGs and OBs (requiring more than 3 days wages for the LPGs 
and just under 8 days wages for the OBs), as was fluticasone/salmeterol 25/250mcg which 
required about 6 days wages for the LPGs and more than 10 days wages to purchase a monthly 
course of the OBs  . 
The first line of management for diabetes mellitus-2 (DM II) was affordable for both the OBs 
and LPGs in all the four regions of Eswatini, with a monthly course of 60 tablets of 
glibenclamide 5mg requiring less than 0.5 days’ wages to purchase. It is worth noting that less 
than 0.8 days’ wages were required to purchase a course of either the OB or LPGs of metformin 
500mg in the four regions. Gliclazide was less affordable and required more than the equivalent 
of the lowest paid unskilled government worker’s single day wage to purchase a course for one 
month of the LPGs. No LPG was found for human insulin (30% regular/70% isophane) in all 
the surveyed areas and the OB required 5.20 days’ wages in Manzini, 5.36 days’ wages in 
Hhohho and 7.37 days’ wages in the Lubombo region. 
Table 5. Affordability of treatments for a family with multiple conditions (consolidated retail 
















Enalapril 20mg od * 30 days 
LPG 74.66 0.9 
OB 164.93 1.9 
 
Diabetes Mellitus II 
 
Metformin 500mg twice daily * 30 days 
LPG 36.60 0.4 
OB 60.47 0.7 
Respiratory Infection 
(Child) 
Amoxicillin + Clavulanic acid 125/31.25mg 3 
times daily * 7 days 
LPG 60.40 0.7 
OB 187.58 2.2 
 
Total 
 LPG 171.66 2.0 
OB 412.98 4.8 
OB, originator brand; LPG, lowest-priced generic equivalent. 
Table 5 illustrates the affordability of a 3-drug regimen when originator brands and lowest price 
generics when purchased from the retail pharmacy sector in Eswatini. The lowest paid 
government worker would have to work 2 days to afford the LPG regimen and in case the LPGs 





The study showed that the overall availability of the LPG medicines in all the regions was 
higher than the recommended minimum availability benchmark set by World Health 
Organisation/Health Action International, of 80%.²⁰ It can be deduced from the results that there 
is promotion of generics’ dispensing as compared to the branded products in all the regions. 
The more affluent settlements are in Hhohho and Manzini regions, and the availability of OBs 
was comparably higher in these 2 regions. 
The overall availability of LPGs was not different in all the regions, however the pharmacies 
located in cities had higher availability than the ones in smaller towns and rural areas for both 
LPGs and OBs. It is commendable that the availability of LPGs on the Essential Medicines List 
(EML) was more than 90% in all regions, and as such in the event of medicines being 
unavailable at government hospitals, patients can access medications at retail pharmacies. 
It was quite interesting to note that the LPGs’ prices were comparable in all the 4 regions and 
the differences reflected were not statistically significant. Although there is currently no price 
regulation administered by the government, ³⁶ the market forces ‘regulate’ the medicines’ prices 
in the Eswatini pharmaceuticals market. 
A careful analysis of the molecules that had large differentials e.g. omeprazole 20mg showed 
that the overseas parallel generic imports were available at a significantly lower price to the 
patients as compared to similar generic molecules that were sourced regionally. The clients in 
the more affluent locations are generally brand-sensitive as compared to patients in the rural 
settings, where outlets can afford to keep the most affordable non-branded import generics. 
There is need for the authorities to ascertain that these lowly priced molecules also meet the 
stipulated quality standards. 
The study showed that generally the OBs patient prices were higher in Eswatini when compared 
to prices of the same prescription molecules in South Africa, and this is not a deviation from 
the expected as literature suggests medicines prices in regulated environments are generally 
lower than in countries with no price regulation.²³ Eswatini procures their OBs from South 
Africa where pricing is regulated and as such the best/lowest cost to the retail outlets for these 
would be at the SEP price and as such it’s expected that the retailing prices will be higher than 
SEP in the Eswatini outlets. Eswatini prescription medicines’ prices have VAT at 0%,³ whereas 
in South Africa all medicines attract VAT at 15%, if the VAT regulation in Eswatini would 
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change from 0% to the standard 15% VAT,²⁴ the Eswatini  prescription medicines’ will become 
more expensive to the end users. 
The Eswatini market is not limited to the South African generic molecules only as they also 
have access to parallel import generics from overseas which were found to be generally cheaper 
than the South African equivalent molecules. The difference in the GDP per Capita per month 
between South Africa and Eswatini needs to be considered, ⁸ as a small price difference may 
turn out to be huge with respect to affordability in the Eswatini context. 
Most first line treatment regimens for NCD’s were generally affordable, requiring less than a 
day’s wages. It is worth noting that more than 60% of  Eswatini’s population lives below the 
upper poverty line of USD 8.21 per capita per month and as such,⁸ treatment regimens 
calculated as affordable may still be way out of the range for the general populace.¹⁶ There is 
usually more than one family member requiring chronic medications, and even though the 
individual courses may be affordable , the combined regimens will be unaffordable. Anti-
epileptic medications and most second line management regimes required more than a day’s 
wages hence unavailability at the public hospitals could lead to patients defaulting their 
treatments.  
Limitations 
Affordability was calculated based on the daily wage of the lowest paid unskilled government 
worker, but a large portion of the labour force  is not employed by the government and the 
minimum wages are way lower than the salary of the lowest paid government worker– thus the 
data may not be a true reflection of affordability in Eswatini. 
Availability refers to the day of data collection at each facility and might not indicate average 
availability over time. Availability and prices data were collected during level 2 lockdown (due 
to the COVID-19 pandemic) when supply chains were disrupted and hence these findings may 
not be a true reflection of the availability throughout the year(Eswatini depends entirely on 
imports as there is no manufacturing of any pharmaceuticals that takes place in the kingdom). 
Recommendations 
Future research should focus on comprehensive national surveys in all public and private 
entities to determine medicines prices, including from the wholesalers. Price components 
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throughout the entire pharmaceutical supply chain should be studied. Focus on these will assist 
in developing policies that will work towards improving affordability and availability. 
Conclusion 
Drug-pricing control by the government is one of the factors responsible for lower retail prices 
in South Africa. The concept of ‘free market economy’ in Eswatini may not be enough to 
regulate the prices of medicines. There is need to develop drug pricing policies that govern the 
whole supply chain,¹⁶ however for that to happen all the necessary data on the current pricing 
structure in the whole pharmaceutical supply chain Eswatini should be gathered. The Medicines 
and Related Substances Act of 2016 makes provision for prescription of a pricing system for 
medicines in Eswatini. ¹⁷ 
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Chapter 4: Synthesis, Conclusion and Recommendations 
 
4.1   Synthesis 
Prices for prescription medicines are a significant obstacle to appropriate medicine use.¹  It is 
not easy to find reliable medicines prices’ information in developing countries, ² including in 
Eswatini. 
Kheder et al. ³ affirm that cross national differences in pharmaceutical prices are of great 
importance as they help governments to come up with appropriate domestic pricing policies. 
However as Mhlanga et al. ⁴ highlighted, there is a need to have reliable evidence on medicines’ 
prices in order to ascertain the type of challenges in a country before deciding on solutions that 
will ensure availability of essential medicines at the lowest price to the consumer. 
Pricing surveys have been used to determine the extent of price differentiation and affordability 
in many countries.⁵˒⁶˒⁷˒⁸ Thus, for Eswatini, the WHO/HAI medicine price survey was used to 
identify medicine pricing and affordability in the Kingdom of Eswatini so as to provide policy 
makers and all stakeholders with evidence to draft policies that may improve availability, 
affordability and accessibility of medicines. 
The aim of this study was to investigate the availability, affordability and prices that people pay 
for medicines from retail pharmacies in different parts of Eswatini. In addition, this study sought 
to ascertain how the medicines’ prices in Eswatini compared to the prices of the same medicines 
in South Africa. 
The study revealed that the overall mean availability of all medicines in the surveyed retail 
pharmacy outlets was (38.5%; SD=20.4%) for OBs and (80.9%; SD=19.0%) for LPGs. The 
overall median MPR in the surveyed pharmacies was 18.61 for the OBs and 4.67 for LPGs. 
Most standard treatments with LPGs cost less than a day’s wage whilst for OB’s cost more than 
a day’s wages. The differences between Eswatini and South African prices were statistically 
significant. 
 
4.2  Conclusions 
Overall, the availability of the surveyed medicines was fairly high in Lubombo and Shiselweni 
regions and high in Manzini and Hhohho; many generic options were available for most of the 
medicines, supporting one of the objectives of the Swaziland National Pharmaceutical Policy 
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(SNPP) to encourage generics prescription and dispensing as well as substitution and thus the 
only barrier to access to medicines would be the cost. 
Medicines’ pricing control by the government is one of the factors responsible for lower retail 
prices in South Africa. .Market forces alone may not be enough to regulate medicines’ pricing 
in the Kingdom of Eswatini. There is need to develop drug pricing policies that govern the 
whole supply chain.¹⁶All the necessary data on the current pricing structure in the whole 
pharmaceutical supply chain should be gathered. The medicines and Related Substances Act of 
Eswatini of 2016 makes provision for prescription of a pricing system for medicines in 
Eswatini. ¹⁷ 
 
4.3  Recommendations 
Future research should focus on comprehensive national surveys in all public and private 
entities to determine medicines prices, including from the wholesalers. Price components 
throughout the entire pharmaceutical supply chain should be studied. Focus on these will assist 
in developing policies that will work towards improving affordability and availability. 
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Appendix D – Data collection tool and informed consent letters 
 
UKZN BIOMEDICAL RESEARCH ETHICS COMMITTEE 
 
APPLICATION FOR ETHICS APPROVAL  
For research with human participants (Biomedical) 
 
INFORMED CONSENT RESOURCE TEMPLATE 
 
Information Sheet and Consent to Participate in Research 
 
Date: 01 February 2020 
 
Dear Pharmacy Owner/Manager 
 
My name is Garikai Shambira, a Master’s in Pharmacy (Pharmacoeconomics) student at the University 
of Kwazulu-Natal (UKZN). My contact details are as follows: Phone number: +268-76488283 and e-
mail address: gs141081@gmail.com. 
  
 
You are being invited to consider participating in a study that involves research on Pharmaceutical Prices 
in the retail pharmacy sector in the Kingdom of Eswatini. The aim and purpose of this research is to 
determine the availability, affordability and the prices patients pay for 50 medicines, in the retail 
pharmacy sector in the Kingdom of Eswatini. The study will compare retail prices in the Kingdom of 
Eswatini, South Africa and Internationally. The study is expected to enroll 25 pharmacies: 10 from 
Manzini region, 6 from Hhohho region, 5 from Lubombo and 4 from Shiselweni region.  
 
It will involve collection of specific data on availability and prices using the WHO/HAI workbook, 
during the visits to outlets. Data on price to patient, availability to patient will be collected. Data will be 
collected for two products, namely the originator brand (OB) and the lowest-priced generic (LPG). The 
following data will be collected using the WHO/HAI workbook, by the researcher during visits to “retail 
pharmacy outlets”; 
 
6. The name of pharmacy, administrative region where located, and whether it is in a large 
city/town, small town or rural area. 
7. Brand/Product name and manufacturer of the lowest priced generic found at the site. 
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8. Availability of the Originator brand and the lowest priced generic. 
9. Pack size and price of the pack found for the originator brand and the lowest priced generic. 
10. Any other comments regarding a given product. 
 
During retail pharmacy outlet visits, data will be recorded on hard copy Medicine Prices Data Collection 
forms; and when less than 50% of medicines are available at a given outlet, the data collector will visit 
a back-up facility and reconduct the survey. The data collector will make sure the data collection forms 
are complete and legible before leaving an outlet.  
 
  
We hope that the study will help in understanding the contribution of the current medicines costs (to the 
patient) to medicines access and to inform policy makers and all stakeholders when selecting options 
that will improve availability, affordability and accessibility of medicines in the Kingdom of Eswatini.  
 
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (approval number_____). 
 
In the event of any problems or concerns/questions you may contact the researcher at; 
 
Consultation Room # 1 
Corner Plaza Wellness Wing, Ezulwini 
Box 3318, Manzini, M300 
Eswatini Kingdom  
Tel+ 268-76488283 or +268- 76025013   
Email: gs141081@gmail.com  
 
 
or the UKZN Biomedical Research Ethics Committee, contact details as follows:  
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
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Email: BREC@ukzn.ac.za  
 
Your participation in this research is entirely voluntary, it is your choice to participate or not. You may 
change your mind later and stop participating even if you agreed earlier and you will not incur any 
penalty. If the researcher fails to get at least 50% of the medicines under study in your facility, the 
researcher may terminate the participant from the study. No expenses will be borne by your outlet if you 
opt to participate in this research. 
 
The information that will be collected from this research will be kept confidential. Information about 
the pharmacy that will be collected during the research will be put away and no one except the researcher 
will have access to it. Any information about your pharmacy will be assigned a random number instead 
of the pharmacy name and anonymized. Only the researcher will know the number of your pharmacy 
and will lock access to the identity. It will not be shared with or given to anyone except to Professor 
Fatima Suleman, who is the research Supervisor. 
 
Data from the hard copies of the medicines prices collection forms will be entered on anonymized 
computer files soon after data collection, and these files will be password protected and only accessible 
to the researcher, research supervisor and the Biomedical Research Ethics Administration if need be, 
but noone else. Measures will be put in place  The hard copies will be stored under lock and key in the 










I                                                                     have been informed about the study entitled ‘Prescription 
Medicines’ Prices in the retail pharmacy sector in the Kingdom of Eswatini: Are people paying more in 
certain Locations?’  by Garikai Shambira. 
 
I understand the purpose and procedures of the study will involve collection of specific data on 
availability and prices using the WHO/HAI workbook, during the visits to outlets. Data on price to 
patient, availability to patient will be collected. Data will be collected for two products, namely the 
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originator brand (OB) and the lowest-priced generic (LPG). The following data will be collected using 
the WHO/HAI workbook, by the researcher during visits to “retail pharmacy outlets”; 
 
1. The name of pharmacy, administrative region where located, and whether it is in a large 
city/town, small town or rural area. 
2. Brand/Product name and manufacturer of the lowest priced generic found at the site. 
3. Availability of the Originator brand and the lowest priced generic. 
4. Pack size and price of the pack found for the originator brand and the lowest priced generic. 
5. Any other comments regarding a given product. 
 
 
I have been given an opportunity to answer questions about the study and have had answers to my 
satisfaction. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw at any time 
without incurring any penalties. I will not bear any expenses by participating in this research. 
 
If I have any further questions/concerns or queries related to the study I understand that I may contact 
the researcher at: 
 
Garikai Shambira 
Consultation Room # 1 
Corner Plaza Wellness Wing, Ezulwini 
Box 3318, Manzini, M300 
Eswatini Kingdom  
Tel+ 268-76488283 or +268- 76025013   
Email: gs141081@gmail.com  
 
 
If I have any questions or concerns about my rights as a study participant, or if I am concerned about an 
aspect of the study or the researchers then I may contact: 
 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
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Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 




____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 



























The format of the compulsory cover letter forms part of your submission. Kindly download and 
complete, in English, the provided cover letter. 
  
Anyone that has made a significant contribution to the research and the paper must be listed as an author 
in your cover letter. Contributions that fall short of meeting the criteria as stipulated in our policy should 
rather be mentioned in the ‘Acknowledgements’ section of the manuscript. 
Read our authorship guidelines and author contribution statement policies. 
 
Original Research Articles 
 
An original research article presents innovative research within the focus and scope of the journal, 
according to a clear and well-structured format. Detailed instructions are given below on the structure 
and contents required. The introduction should argue for the social and scientific value of the research 
and end with the aim and objectives of the study. Any conceptual or theoretical framework can also be 
included in the introduction. The methods section should be structured according to the following sub-
headings: study design, setting, study population and sampling strategy, intervention (if appropriate), 
data collection, and data analysis. Occasionally a different structure may be required, for example, in 
quality improvement or participatory action research. The methods should be followed by a section on 
ethical considerations. After this, the results are presented. The article should end with a discussion 
section that summarises the key findings, and then discusses these findings, the strengths and limitations 
of the study, and any implications or recommendations. This should be followed by a conclusion, 
acknowledgements and references sections. 
  
Word limit 3500-7000 words (excluding the structured abstract and references) 
Structured abstract 250 words to cover a Background, Aim, Setting, Methods, Results and Conclusion 
References 60 or less 
Tables/Figures no more than 7 Tables/Figure 
Ethical statement should be included in the manuscript 
Compulsory supplementary file ethical clearance letter/certificate 
Language only manuscripts presented in English or French will be considered 
  
 
